VisionPlus India

References 1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042. DOI: 10.1016/j.ophtha.2016.01.006 2. Based on the number of publications in peer-reviewed publications according to HOYA’s data on file as of May 2025. 3. Leung et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Abstract presented at ARVO. Available at: https://www.hoyavision.com/globalassets/__regional-assets/global/arvo-2025/leung-et-al.-dims- 8y-study-arvo-2025-abstract.pdf (Accessed July 2025) 4. Determined using available published evidence of myopia management spectacle lenses as of May 2025. 5. Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. British Journal of Ophthalmology Published Online First: 17 March 2021. doi: 10.1136/bjophthalmol-2020-317664 6. Conway, M. Increasing myopia and associations with deprivation and rural/urban environments in children aged 3.5-5.5 years in Scotland. IMC Conference Presentation (2024) https://www.hoyavision.com/visionary-knowlegde/blogs-and-article/conference-imc-2024/ (accessed on July 2025) 7. Hsin-Yu Yang, Der-Chong Tsai, Yu-Chieh Yang,C hiao-Yu Wang. Preliminary results and adaptability to the Defocus Incorporated Multiple Segments spectacle lenses among pre-myopic children of preschool age. IMC Conference Presentation (2024) https://www.hoyavision.com/visionary-knowlegde/blogs-and-article/ conference-imc-2024/ (accessed on July 2025) Three ways we’re building confidence Sponsored content through evidence in myopia management With myopia expected to affect half of the global population by 2050 1 , Eye Care Professionals (ECPs) need the latest evidence at their fingertips to tackle its burden and improve outcomes for every child with personalised care. At HOYA Vision Care, I’m proud to lead our efforts to inform ECPs of the latest innovations with our Confidence through Evi- dence program, a world-class scientifically-driven myopia management research program with 90+ scientific publications. . 2 Here’s three important things to know about the program. The longest-running study of myopia control spectacle lenses Our MiYOSMART spectacle lenses are supported by 8 years of clinical evidence demonstrating their sustained effectiveness – the longest-running clinical study on myopia control spectacle lenses to date. 3,4,12 These findings provide crucial information and guidance for ECPs and parents committed to protecting children’s vision health for the future. We’re building evidence on approaches in tailored myopia control We’re constantly researching new treatment regimens to provide ECPs with evidence-backed solutions that can be tailored to each child’s individual needs. This includes combining MiYOSMART’s D.I.M.S. Technology with 0.025% 5 atropine eye drops, which our ASPECT trial demonstrated reduced axial elongation in children with myopia progression versus atropine alone. We’re deepening understanding of how myopia develops We’re committed to expanding the understanding of myopia development and its progression in children all over 6 the world, from rural to urban settings. Our ultimate aim is to prevent myopia development and halt myopia progression as earlier as possible. In a first-of-its-kind pilot study, it was demonstrated the potential of MiYOSMART myopia control spectacle lenses to delay myopia’s onset in pre-myopic preschool-aged children, with spherical 7 equivalent refraction (SER) remaining stable over nine months. With these studies, we’re proud to deliver on our mission to evidence-backed myopia control innovations that protect the long-term vision and quality of life for every child. 1 2 3 For more information about MiYOSMART, scan the QR code or visit miyosmart.com Product Disclaimer: MiYOSMART myopia control spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S. By Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care